top of page
Elios_Logo_Therapeutics_Primary_2000px_RGB_WebUse.png

August 3, 2023

Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis

Journal for ImmunoTherapy of Cancer | Carpenter, et al.

READ MORE

November 6, 2021

Randomized Trial of Tumor Lysate Particle Only Vaccine vs. Tumor Lysate Particle-loaded, Dendritic Cell Vaccine to Prevent Recurrence of Resected Stage III/IV Melanoma: 36-MonthAnalysis - Society for Immunotherapy of Cancer

Journal for ImmunoTherapy of Cancer | Carpenter, et al.

READ MORE

October 10, 2021

Tumor Lysate Particle Only Vaccine (TLPO) vs. Tumor Lysate Particle-loaded, Dendritic Cell (TLPLDC) Vaccine to Prevent Recurrence in Resected Stage III/IV Melanoma Patients: Results of a Phase I/IIaTrial

Carpenter et al.

READ MORE

June 9, 2021

American Society of Clinical Oncology - The influence of harvest method on dendritic cell function and clinical outcomes in a randomized trial of a dendritic cell vaccine to prevent recurrences in high-risk melanoma

Journal of Clinical Oncology | Adams et al.

READ MORE

May 4, 2021

Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis

Cancer Medicine | Chick et al.

READ MORE

PUBLICATIONS & PRESENTATIONS

CONTACT US

We would love to hear from you. Tell us a little about yourself and we will reach out.

Thanks for your message!

Elios_Logo_Therapeutics_Primary_2000px_RGB_WebUse.png

Elios Therapeutics, LLC
​111 Smith Hines Road, Suite E

Greenville, SC 29607

bottom of page